GlaxoSmithKline Ebola Vaccine Being Fast-Tracked for Human Trials

Human trials of an Ebola vaccine from GlaxoSmithKline are being fast-tracked on growing concern over the outbreak of the disease in West Africa that has killed more than 1,400 people.
Author:
Publish date:

Human trials of an Ebola vaccine from GlaxoSmithKline are being fast-tracked on growing concern over the outbreak of the disease in West Africa that has killed more than 1,400 people. GlaxoSmithKline says human trials of the candidate vaccine are to be accelerated with funding from an international consortium. The vaccine could be given to healthy volunteers in the UK, Gambia and Mali as early as September. The consortium's funding will also enable manufacturing to begin of up to around 10,000 additional doses of the vaccine so that if the trials are successful, stockpiles could be immediately available to create an emergency immunization program for high-risk communities.